The existence of a cardiomyopathy of obesity is supported by a range of evidence: epidemiologic study findings, which have shown an association between obesity and heart failure; ...

Obesity has an important influence on the development of heart failure, and is recognized as a risk factor for heart failure in the ACC/AHA heart failure guidelines. 1 Obesity cardiomyopathy ...

Potential Positives. Data published in a peer-reviewed journal support the efficacy of ZyVersa’s Inflammasome ASC Inhibitor IC 100 as a potential treatment for obesity-associated cardiomyopathy ...

Obesity cardiomyopathy (OCM) was identified as a distinct pathology associated with sudden cardiac death (SCD) based on records from a national referral center in the U.K. Autopsies showed that ...

We conducted the STEP-HFpEF DM (Semaglutide Treatment Effect in People with Obesity and Heart Failure with Preserved Ejection Fraction and Diabetes Mellitus) trial, a double-blind, randomized ...

In obesity-associated cardiomyopathy (OAC), heart muscle is structurally and functionally abnormal, impairing the ability to effectively pump blood. Five-year survival rate is less than 50%, with ...

We conducted the Effect of Semaglutide 2.4 mg Once Weekly on Function and Symptoms in Subjects with Obesity-related Heart Failure with Preserved Ejection Fraction (STEP-HFpEF) trial, a randomized ...

ZyVersa Therapeutics (ZVSA) highlights newly published animal model data demonstrating that inflammasome inhibition attenuates obesity-associated cardiomyopathy, which has a 5-year survival rate ...